Condition: ROSAH · Sponsor: Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm)
The purpose of this study is to evaluate the safety and tolerability of DF-003 in retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and migraine headache (ROSAH) syndrome patients.
This description comes directly from the study's public registry record.
Kenneth Truitt, MD · 732-221-7104 · kenneth.truitt@drug-farm.com
Always discuss trial participation with your own doctor first.
| National Institutes of Health Clinical Center | Bethesda, Maryland, United States | Withdrawn |
| Duke Eye Center - Duke University Hospital | Durham, North Carolina, United States | Recruiting |
| John A. Moran Eye Center - University of Utah Health | Salt Lake City, Utah, United States | Recruiting |
| Save Sight Institute - University of Sydney Eye Hospital | Sydney, New South Wales, Australia | Recruiting |
| Peking Union Medical College Hospital | Beijing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06395285